Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
15,213 questions in 2,394 reviews
current versionsNo studies 15,213 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Duplex ultrasound plus pulse palpation and arterial pressure index (ABI or TBI) vs pulse palpation plus arterial pressure index (ABI or TBI) (short term) Adverse events resulting from DUS surveillance · people who underwent a lower limb revascularisation Duplex ultrasound for surveillance of lower limb revascularisation (2023) · Cochrane | no estimate extracted | NR | No studies |
Duplex ultrasound plus pulse palpation and arterial pressure index (ABI or TBI) vs pulse palpation plus arterial pressure index (ABI or TBI) (short term) Functional walking ability · people who underwent a lower limb revascularisation Duplex ultrasound for surveillance of lower limb revascularisation (2023) · Cochrane | no estimate extracted | NR | No studies |
Duplex ultrasound plus pulse palpation and arterial pressure index (ABI or TBI) vs pulse palpation plus arterial pressure index (ABI or TBI) (short term) Clinical severity scales · people who underwent a lower limb revascularisation Duplex ultrasound for surveillance of lower limb revascularisation (2023) · Cochrane | no estimate extracted | NR | No studies |
Duplex ultrasound plus pulse palpation and arterial pressure index (ABI or TBI) vs pulse palpation plus arterial pressure index (ABI or TBI) (long term) Limb salvage rate · people who underwent a lower limb revascularisation Duplex ultrasound for surveillance of lower limb revascularisation (2023) · Cochrane | no estimate extracted | NR | No studies |
Weekly educational texts messages vs once every other week educational text messages Flare‐ups or relapse (continuous) · people with inflammatory bowel disease Patient education interventions for the management of inflammatory bowel disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Weekly educational texts messages vs once every other week educational text messages Flare‐ups or relapse (dichotomous) · people with inflammatory bowel disease Patient education interventions for the management of inflammatory bowel disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Web‐based patient education vs other delivery of patient education Flare‐ups or relapse (continuous) · people with inflammatory bowel disease Patient education interventions for the management of inflammatory bowel disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Web‐based patient education vs other delivery of patient education Flare‐ups or relapse (dichotomous) · people with inflammatory bowel disease Patient education interventions for the management of inflammatory bowel disease (2023) · Cochrane | no estimate extracted | NR | No studies |
High‐dose vs standard‐dose strategies Major neurodevelopmental disability in children aged 18 to 24 months CA · preterm infants at risk for apnea of prematurity Caffeine dosing regimens in preterm infants with or at risk for apnea of prematurity (2023) · Cochrane | no estimate extracted | NR | No studies |
High‐dose vs standard‐dose strategies Mortality or major neurodevelopmental disability in children aged 18 to 24 months and 3 to 5 years CA · preterm infants at risk for apnea of prematurity Caffeine dosing regimens in preterm infants with or at risk for apnea of prematurity (2023) · Cochrane | no estimate extracted | NR | No studies |
High‐dose vs standard‐dose strategies Side effects (tachycardia, agitation, or feed intolerance) leading to a reduction in dose or withholding of caffeine · preterm infants at risk for apnea of prematurity Caffeine dosing regimens in preterm infants with or at risk for apnea of prematurity (2023) · Cochrane | no estimate extracted | NR | No studies |
High‐dose vs standard‐dose strategies Seizures (clinically diagnosed; diagnosed by electroencephalography) · preterm infants at risk for apnea of prematurity Caffeine dosing regimens in preterm infants with or at risk for apnea of prematurity (2023) · Cochrane | no estimate extracted | NR | No studies |
High‐dose vs standard‐dose strategies Major neurodevelopmental disability in children aged 18 to 24 months CA · preterm infants with or at risk for apnea of prematurity Caffeine dosing regimens in preterm infants with or at risk for apnea of prematurity (2023) · Cochrane | no estimate extracted | NR | No studies |
High‐dose vs standard‐dose strategies Major neurodevelopmental disability in children aged 3 to 5 years CA · preterm infants with or at risk for apnea of prematurity Caffeine dosing regimens in preterm infants with or at risk for apnea of prematurity (2023) · Cochrane | no estimate extracted | NR | No studies |
High‐dose vs standard‐dose strategies Major neurodevelopmental disability in children aged 18 to 24 months CA · preterm infants with or at risk for apnea of prematurity Caffeine dosing regimens in preterm infants with or at risk for apnea of prematurity (2023) · Cochrane | no estimate extracted | NR | No studies |
High‐dose vs standard‐dose strategies Mortality or major neurodevelopmental disability in children aged 18 to 24 months and 3 to 5 years CA · preterm infants with or at risk for apnea of prematurity Caffeine dosing regimens in preterm infants with or at risk for apnea of prematurity (2023) · Cochrane | no estimate extracted | NR | No studies |
High‐dose vs standard‐dose strategies Duration of hospital stay (days) · preterm infants with or at risk for apnea of prematurity Caffeine dosing regimens in preterm infants with or at risk for apnea of prematurity (2023) · Cochrane | no estimate extracted | NR | No studies |
High‐dose vs standard‐dose strategies Seizures (clinically diagnosed; diagnosed by electroencephalography) · preterm infants with or at risk for apnea of prematurity Caffeine dosing regimens in preterm infants with or at risk for apnea of prematurity (2023) · Cochrane | no estimate extracted | NR | No studies |
High‐dose vs standard‐dose strategies Major neurodevelopmental disability in children aged 18 to 24 months CA · preterm infants with or at risk for apnea of prematurity Caffeine dosing regimens in preterm infants with or at risk for apnea of prematurity (2023) · Cochrane | no estimate extracted | NR | No studies |
High‐dose vs standard‐dose strategies Major neurodevelopmental disability in children aged 3 to 5 years CA · preterm infants with or at risk for apnea of prematurity Caffeine dosing regimens in preterm infants with or at risk for apnea of prematurity (2023) · Cochrane | no estimate extracted | NR | No studies |
High‐dose vs standard‐dose strategies Mortality or major neurodevelopmental disability in children aged 18 to 24 months and 3 to 5 years CA · preterm infants with or at risk for apnea of prematurity Caffeine dosing regimens in preterm infants with or at risk for apnea of prematurity (2023) · Cochrane | no estimate extracted | NR | No studies |
High‐dose vs standard‐dose strategies Side effects (tachycardia, agitation, or feed intolerance) leading to a reduction in dose or withholding of caffeine · preterm infants with or at risk for apnea of prematurity Caffeine dosing regimens in preterm infants with or at risk for apnea of prematurity (2023) · Cochrane | no estimate extracted | NR | No studies |
High‐dose vs standard‐dose strategies Duration of hospital stay (days) · preterm infants with or at risk for apnea of prematurity Caffeine dosing regimens in preterm infants with or at risk for apnea of prematurity (2023) · Cochrane | no estimate extracted | NR | No studies |
High‐dose vs standard‐dose strategies Seizures (clinically diagnosed; diagnosed by electroencephalography) · preterm infants with or at risk for apnea of prematurity Caffeine dosing regimens in preterm infants with or at risk for apnea of prematurity (2023) · Cochrane | no estimate extracted | NR | No studies |
High‐dose vs standard‐dose strategies Mortality or major neurodevelopmental disability in children aged 18 to 24 months and 3 to 5 years CA · preterm infants with or at risk for apnea of prematurity Caffeine dosing regimens in preterm infants with or at risk for apnea of prematurity (2023) · Cochrane | no estimate extracted | NR | No studies |
Silicone gel sheeting vs non‐silicone gel sheeting treatment Adherence to treatment · people with keloid scars Silicone gel sheeting for treating keloid scars (2023) · Cochrane | no estimate extracted | NR | No studies |
Silicone gel sheeting vs non‐silicone gel sheeting treatment Health‐related quality of life · people with keloid scars Silicone gel sheeting for treating keloid scars (2023) · Cochrane | no estimate extracted | NR | No studies |
Silicone gel sheeting vs intralesional injections of triamcinolone acetonide Scar severity validated by participants · people with keloid scars Silicone gel sheeting for treating keloid scars (2023) · Cochrane | no estimate extracted | NR | No studies |
Silicone gel sheeting vs intralesional injections of triamcinolone acetonide Adverse events · people with keloid scars Silicone gel sheeting for treating keloid scars (2023) · Cochrane | no estimate extracted | NR | No studies |
Silicone gel sheeting vs intralesional injections of triamcinolone acetonide Adherence to treatment · people with keloid scars Silicone gel sheeting for treating keloid scars (2023) · Cochrane | no estimate extracted | NR | No studies |
Silicone gel sheeting vs intralesional injections of triamcinolone acetonide Health‐related quality of life · people with keloid scars Silicone gel sheeting for treating keloid scars (2023) · Cochrane | no estimate extracted | NR | No studies |
Silicone gel sheeting vs no treatment Scar severity validated by participants · people with keloid scars Silicone gel sheeting for treating keloid scars (2023) · Cochrane | no estimate extracted | NR | No studies |
Silicone gel sheeting vs no treatment Adverse events · people with keloid scars Silicone gel sheeting for treating keloid scars (2023) · Cochrane | no estimate extracted | NR | No studies |
Silicone gel sheeting vs no treatment Adherence to treatment · people with keloid scars Silicone gel sheeting for treating keloid scars (2023) · Cochrane | no estimate extracted | NR | No studies |
Silicone gel sheeting vs no treatment Health‐related quality of life · people with keloid scars Silicone gel sheeting for treating keloid scars (2023) · Cochrane | no estimate extracted | NR | No studies |
Silicone gel sheeting vs non‐silicone gel sheeting treatment Scar severity validated by participants · people with keloid scars Silicone gel sheeting for treating keloid scars (2023) · Cochrane | no estimate extracted | NR | No studies |
Silicone gel sheeting vs non‐silicone gel sheeting treatment Adverse events · people with keloid scars Silicone gel sheeting for treating keloid scars (2023) · Cochrane | no estimate extracted | NR | No studies |
Olokizumab vs standard care/placebo Clinical improvement D60 or more ‐ not reported · people with mild/moderate/severe/critical COVID‐19 Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review (2023) · Cochrane | no estimate extracted | NR | No studies |
Olokizumab vs standard care/placebo WHO progression score (level 7 or above) D28 ‐ not reported · people with mild/moderate/severe/critical COVID‐19 Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review (2023) · Cochrane | no estimate extracted | NR | No studies |
Olokizumab vs standard care/placebo All‐cause mortality D60 or more ‐ not reported · people with mild/moderate/severe/critical COVID‐19 Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review (2023) · Cochrane | no estimate extracted | NR | No studies |
Olokizumab vs standard care/placebo Adverse events ‐ not reported · people with mild/moderate/severe/critical COVID‐19 Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review (2023) · Cochrane | no estimate extracted | NR | No studies |
Siltuximab vs standard care/placebo Clinical improvement D60 or more ‐ not reported · people with mild/moderate/severe/critical COVID‐19 Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review (2023) · Cochrane | no estimate extracted | NR | No studies |
Siltuximab vs standard care/placebo Adverse events ‐ not reported · people with mild/moderate/severe/critical COVID‐19 Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review (2023) · Cochrane | no estimate extracted | NR | No studies |
Levilimab vs standard care/placebo Clinical improvement D60 or more ‐ not reported · people with mild/moderate/severe/critical COVID‐19 Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review (2023) · Cochrane | no estimate extracted | NR | No studies |
Levilimab vs standard care/placebo WHO progression score (level 7 or above) D28 ‐ not reported · people with mild/moderate/severe/critical COVID‐19 Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings for nasal irrigation with topical steroids plus sinus surgery vs nasal irrigation with topical steroids alone Mortality · children and adults diagnosed with cystic fibrosis and chronic rhinosinusitis with nasal polyposis Surgery for nasal polyposis in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Doxapram vs no treatment, placebo, methylxanthine (including theophylline, aminophylline, or caffeine), or 4a.Death at any time during initial hospitalization – doxapram compared to no treatment for the treatment of apnea · treatment of apnea Doxapram for the prevention and treatment of apnea in preterm infants (2023) · Cochrane | no estimate extracted | NR | No studies |
Doxapram vs no treatment, placebo, methylxanthine (including theophylline, aminophylline, or caffeine), or 4b. Death at any time during initial hospitalization – doxapram compared to alternative treatment for the treatment of apnea · treatment of apnea Doxapram for the prevention and treatment of apnea in preterm infants (2023) · Cochrane | no estimate extracted | NR | No studies |
Doxapram vs no treatment, placebo, methylxanthine (including theophylline, aminophylline, or caffeine), or 4c. Death at any time during initial hospitalization – doxapram as an adjunct to methylxanthine compared to methylxanthine alone for the treatment of apnea · treatment of apnea Doxapram for the prevention and treatment of apnea in preterm infants (2023) · Cochrane | no estimate extracted | NR | No studies |
Doxapram vs no treatment, placebo, methylxanthine (including theophylline, aminophylline, or caffeine), or 5a. Moderate‐to‐severe neurodevelopmental disability or intellectual impairment after 2 years of age – doxapram compared to no treatment for the treatment of apnea · treatment of apnea Doxapram for the prevention and treatment of apnea in preterm infants (2023) · Cochrane | no estimate extracted | NR | No studies |